https://www.biopharmawatch.com/news/MLYS/lorundrostat-transform-htn-trial-results-aha-2026 BiopharmaWatch en 2026-11-08T21:35:00.000Z Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026 https://www.biopharmawatch.com/news/VIR/vir-biotechnology-eclipse-1-trial-results BiopharmaWatch en 2026-11-08T21:15:00.000Z Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta https://www.biopharmawatch.com/news/RDNT/radnet-third-quarter-results-2026 BiopharmaWatch en 2026-11-08T21:01:00.000Z RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges https://www.biopharmawatch.com/news/REGN/cid-eb-sirna-normalizes-liver-fat-masld-patients BiopharmaWatch en 2026-11-08T21:00:00.000Z CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD https://www.biopharmawatch.com/news/RCEL/avita-medical-host-investor-webinar-briefing-20261108 BiopharmaWatch en 2026-11-08T20:30:00.000Z AVITA Medical to Host Investor Webinar Briefing https://www.biopharmawatch.com/news/JNJ/jnj-reports-73-percent-psa-response-rate BiopharmaWatch en 2026-11-08T16:00:00.000Z Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer https://www.biopharmawatch.com/news/CGEM/velinotamig-complete-renal-responses-sle-acr-2026 BiopharmaWatch en 2026-11-08T15:30:11.000Z Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-update-zugocabtagene-geleucel BiopharmaWatch en 2026-11-08T15:30:00.000Z CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases https://www.biopharmawatch.com/news/CABA/cabaletta-bio-resec-cel-phase-1-2-data-acr-2026 BiopharmaWatch en 2026-11-08T15:00:00.000Z Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-plozasiran-data-presentation BiopharmaWatch en 2026-11-07T21:15:00.000Z Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates https://www.biopharmawatch.com/news/JNJ/j-j-icotyde-improves-psoriatic-arthritis-activity BiopharmaWatch en 2026-11-07T15:03:00.000Z Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide https://www.biopharmawatch.com/news/JNJ/jnj-nipocalimab-phase-2-sjogrens-disease-data BiopharmaWatch en 2026-11-07T15:03:00.000Z Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients https://www.biopharmawatch.com/news/ARGX/argenx-phase-3-alkivia-data-acr-convergence-2026 BiopharmaWatch en 2026-11-07T15:01:00.000Z argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis https://www.biopharmawatch.com/news/OGN/real-world-evidence-hadlima-acr-meeting BiopharmaWatch en 2026-11-07T15:00:00.000Z New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System https://www.biopharmawatch.com/news/LFMD/lifemd-reschedules-q3-2026-earnings-call BiopharmaWatch en 2026-11-07T00:25:00.000Z LifeMD Reschedules Third Quarter 2026 Earnings Release and Conference Call to November 12, 2026 https://www.biopharmawatch.com/news/BFRI/biofrontera-third-quarter-2026-results BiopharmaWatch en 2026-11-06T23:08:00.000Z Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026 https://www.biopharmawatch.com/news/ANGO/angiodynamics-inducement-grants-ceo-appointment BiopharmaWatch en 2026-11-06T23:00:00.000Z AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-q3-2026-results BiopharmaWatch en 2026-11-06T22:40:00.000Z bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization https://www.biopharmawatch.com/news/SRZN/surrozen-present-upcoming-healthcare-investor-conference-20261106 BiopharmaWatch en 2026-11-06T21:40:00.000Z Surrozen to Present at Upcoming Healthcare Investor Conference